Skip to main content
OpenTrials
Completed

NCT Number: NCT00229268

Research on the Nature, Diagnosis, and Treatment of Obesity and Diabetes

The purpose of this study is to determine whether the level of FOXA2 expression in fat tissue is a biomarker of insulin resistance. To test this hypothesis, we will perform euglycemic-hyperinsulinemic clamps in normal and obese human subjects to calculate insulin sensitivity, and see if insulin sensitivity correlates with the FOXA2 expression in subcutaneous fat.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–45 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Rockefeller University Hospital

New York, 10021, United States

About this study

The investigators at Rockefeller University Hospital are engaged in research on the nature, diagnosis and treatment of obesity and diabetes. The investigators are trying to find out why insulin, a blood sugar lowering hormone that is released by the pancreas following a meal, does not work effectively in individuals with obesity or type 2 diabetes. The investigators have recently discovered a protein in fat cells of obese mice that helps fat cells to take up and break down sugar from the blood. This protein (called FOXA2) also prevents the generation of more fat cells. FOXA2 is only present in obese mice, but absent from fat stores of lean animals. Insulin can stimulate the production of FOXA2 in fat cells. Furthermore, the levels of FOXA2 protein correlate with the degree of blood insulin levels. In this study, we are would like to determine whether FOXA2 is also produced in fat cells of humans, and if its level correlates with the degree of obesity and insulin resistance.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy individuals
  • Age 21-45 years old
  • BMI: either < 25, or 30-35, or > 40
  • All patients must be willing and able to sign an informed consent form -

Exclusion criteria

  • Chronic illnesses other the than mild forms of illnesses related to obesity, such as hypertension, hyperlipidemia, and others, that do not require medical treatment
  • Diabetes mellitus previously diagnosed as per subject report or an abnormal 2 hour OGTT at screening
  • Chronic drug treatment for any medical condition
  • Active weight reduction of more than 7 pounds in the last 3 months
  • History of bleeding or blood clotting disorders
  • Subjects with hemoglobin <8.5 gm/dl
  • Changes in smoking habits for the last 6 months
  • Current pregnancy or current breast-feeding in women
  • Allergic reaction to local anesthetics
  • History of anaphylaxis or anaphylactic-like reactions
  • Tendency to form scars (keloids) easily
  • Irregular menses
  • HIV and hepatitis B or C positive subjects -

Sponsors and collaborators

Lead sponsor

Rockefeller University

Other

Registry information

Official study title

FOXA2 Expression in Adipose Tissue of Human Subjects With Obesity/Insulin-Resistance

Important dates

Study start
2005
Study completion
2010
First posted
Sep 29, 2005
Registry last updated
Jun 1, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.